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OBJECTIVES We investigated the in vivo effects of tissue factor (TF) inhibition with recombinant tissue
factor pathway inhibitor (rTFPI) on acute thrombus formation and intimal hyperplasia and
the in vitro effects on smooth muscle cell migration and proliferation.
BACKGROUND Inhibition of TF with TFPI has been shown to reduce intimal hyperplasia in experimental
models. However, its effects after coronary angioplasty and the cellular mechanisms involved
have not been investigated.
METHODS Twenty-three swine underwent multivessel coronary angioplasty. Fifteen (n 5 25 arteries)
were euthanized at 72 h to assess thrombus formation and eight (n 5 24 arteries) at 28 days
to assess intimal hyperplasia. Animals in the 72-h time point received: 1) human rTFPI
(0.5 mg bolus plus 25 mg/kg/min continuous infusion for 3 days) plus heparin (150 IU/kg
intravenous bolus) plus acetyl salicylic acid (ASA) (325 mg/day); 2) rTFPI regimen plus ASA
and 3) heparin (150 IU/kg intravenous bolus) plus ASA.
RESULTS On histology the control group had evidence of mural thrombus (area 0.8 6 0.4 mm2).
Treatment with TFPI plus heparin abolished thrombus formation (mean area: 0.0 6
0.0 mm2, p , 0.05) but was associated with prolonged activated partial thromboplastin time
and extravascular hemorrhage. Recombinant TFPI alone inhibited thrombosis without
bleeding complications (mean area: 0.03 6 0.02 mm2, p , 0.05 vs. control). Animals in the
28-day time point received continuous intravenous infusion of rTFPI or control solution for
14 days. Tissue factor pathway inhibitor reduced neointimal formation with mean intimal
area of 1.2 6 0.3 mm2 versus 3.2 6 0.4 mm2 in the control group; p , 0.01. Recombinant
TFPI had no effect on human aortic smooth muscle cell growth but inhibited platelet-derived
growth factor BB-induced migration.
CONCLUSIONS Inhibition of TF with rTFPI can prevent acute thrombosis and intimal hyperplasia after
injury. Tissue factor plasma inhibitor may prove useful as an adjunct to intracoronary
interventions. (J Am Coll Cardiol 2000;36:2303–10) © 2000 by the American College of
Cardiology
Percutaneous transluminal coronary angioplasty is the pro-
cedure of choice for treating coronary stenosis—almost one
million procedures are performed each year worldwide (1).
Many innovations, notably coronary stenting and adjunctive
antithrombotic therapy, have made percutaneous coronary
interventions safer and more effective, expanding their
indications; however, restenosis continues to be an impor-
tant limitation (2).
Thrombus formation is a frequent feature after arterial
injury (3–6). Thrombin generation, platelet activation and
fibrin deposition are the main events leading to acute
thrombosis (7,8). Inhibition of thrombosis after angioplasty
has been associated with a decrease in restenosis (9–12).
Thrombin, in addition to being a powerful activator of
platelets, induces the release of mitogenic factors, such as
platelet-derived growth factor (PDGF) from vascular
smooth muscle cells (SMC) (13) and has been implicated in
SMC migration and proliferation (14). Inhibition of throm-
bin generation in vivo is, therefore, considered an important
therapeutic target in the sequence of events leading to
intimal hyperplasia and restenosis after arterial injury.
Tissue factor (TF) is a membrane-bound glycoprotein
that activates the coagulation cascade. Tissue factor and
factor VII/VIIa form complexes that catalyze the activation
of factors IX and X, leading to thrombin generation (15,16).
Balloon injury is associated with rapid induction of TF
mRNA and activity throughout the arterial wall (17,18).
Tissue factor content of human atherosclerotic plaques
correlates with thrombogenicity in an ex vivo perfusion
system (19). Therefore, blockade of TF activity may reduce
thrombosis.
Tissue factor pathway inhibitor (TFPI) is the principle
physiologic inhibitor of the TF-factor VII/VIIa complex
and is found mainly in endothelial cells (20). Tissue factor
pathway inhibitor therapy has been proven beneficial in
deep vein thrombosis (21) in preventing arterial reocclusion
after fibrinolysis (22) and in reducing intimal hyperplasia in
experimental models of arterial injury (9,10). Using an ex
vivo perfusion system we have shown previously that specific
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inhibition of TF with TFPI reduces thrombogenicity of
disrupted human aortic atherosclerotic plaques (23).
In this study we investigated the effects of TF inhibition
in a porcine model of coronary angioplasty. Human recom-
binant TFPI (rTFPI) inhibited acute thrombus formation
and reduced intimal hyperplasia. Tissue factor pathway
inhibitor had a synergistic anticoagulant effect when given
in combination with unfractionated heparin. In addition,
TFPI inhibited migration of human SMC in culture. These
findings support TF inhibition as a potential therapeutic
approach to prevent acute thrombosis and restenosis after
coronary interventions.
METHODS
Animals. Yorkshire-albino swine, 27 to 32 kg body weight
(Animal Biotech Industries, Danboro, Pennsylvania), were
housed at the Center for Laboratory Animal Sciences at
The Mount Sinai Medical Center, New York, New York,
received standard chow (PMI Nutrition International, St.
Louis, Missouri) and tap water ad libitum. Procedures and
animal care were approved by the Institutional Animal Care
and Use Committee and were in accordance with the
“Guide for the Care and Use of Laboratory Animals” (24).
rTFPI. Recombinant tissue factor pathway inhibitor was
provided by Chiron Corporation, Emeryville, California.
Human rTFPI was expressed in Escherichia coli as a non-
glycosylated protein with additional alanine attached to the
amino-terminus of wild-type TFPI. The compound was
purified by anion exchange chromatography, refolded
through a disulfide interchange reaction and resolved from
relatively inactive and misfolded molecules on a cation-
exchange chromatography column (25). Human rTFPI was
dissolved in buffer solution containing 200 mmol/L argi-
nine, 20 mM sodium citrate buffer, 0.01% polysorbate-80
and 150 mM NaCl (pH 5 7.2) at a final concentration of
5 mg/mL. The same buffer was used as control solution.
Experimental design. Effect of TF inhibition on acute
thrombus formation. Animals (n 5 15) were divided into
the following three groups according to treatment: 1)
rTFPI, heparin and acetyl salicylic acid (ASA); 2) rTFPI
and ASA and 3) control (vehicle solution), heparin and
ASA. Recombinant tissue factor pathway inhibitor was
administered as an intravenous bolus of 0.5 mg/kg of body
weight, 10 min before angioplasty followed by constant
infusion of 25 mg/kg/h for 72 h. Unfractionated heparin was
given as a single bolus of 150 IU/kg intravenous 10 min
before the procedure. Acetyl salicylic acid was given per os,
325 mg/day, beginning 24 h before angioplasty and con-
tinuing until euthanasia. The vehicle solution (control) was
given as an intravenous bolus before angioplasty, followed
by an infusion for 72 h, using a volume equivalent to the
rTFPI solution. Animals were euthanized 72 h after angio-
plasty to analyze acute thrombus formation.
Effect of TF inhibition on intimal hyperplasia. Animals
(n 5 8) were assigned to two treatment groups: 1) bolus plus
constant intravenous infusion of rTFPI for 14 days and
ASA and 2) bolus of unfractionated heparin plus intrave-
nous infusion of vehicle solution and ASA as control
treatment. All drugs were administered at the same doses
specified above. Animals were euthanized 28 days after
angioplasty to assess intimal hyperplasia.
Interventional procedures. For coronary balloon angio-
plasty, the pigs were sedated initially with ketamine (intra-
venous, 20 mg/kg body weight) followed by sodium pento-
barbital (intravenous, 25 mg/kg), intubated and ventilated
mechanically. Anesthesia was maintained with inhaled
isoflurane (Forane, Ohmeda Caribe, Guayama, Puerto
Rico). The right carotid artery and internal jugular vein
were exposed through a median neck incision. Both vessels
were cannulated, and each line was tunneled subcutaneously
to exit through a posterior neck incision. The carotid
cannula was used for blood sampling; the venous cannula
was attached to an infusion pump (Harvard Apparatus,
Holliston, Massachusetts). Coronary angioplasty was per-
formed by three inflations of a 4.0 3 2.0 mm balloon
(Olimpix, Cordis Corp., Miami, Florida) to 8 to 10 atms, as
described previously (12). Fluoroscopy-guided angiographic
examinations were performed before, during and after
percutaneous transluminal coronary angioplasty.
Tissue harvesting and histology. After anesthesia with
ketamine and pentobarbital, the aorta and heart were
exposed through a median sternotomy. Animals were then
euthanized with an overdose of pentobarbital (Sleepaway,
Fort Dodge Laboratories, Fort Dodge, New Jersey). The
heart and ascending aorta were excised immediately and
perfusion-fixed with 4% paraformaldehyde in phosphate
buffered saline. Specimens were kept in fresh fixative solu-
tion overnight. Coronary segments of interest were excised,
cross-sectioned at 2-mm intervals and processed for paraffin
embedding. Sections were cut sequentially and stained with
combined Masson elastin trichrome and hematoxylin-eosin.
Morphometry. Arterial specimens were analyzed by two
investigators blinded to the study design. For each coronary
specimen the section with maximal luminal narrowing was
selected. Degree of arterial injury induced by angioplasty
was classified according to an injury score modified from
Schwartz et al. (26): 0 5 intact endothelium, 1 5 endothe-
Abbreviations and Acronyms
aPTT 5 activated partial thromboplastin time
ASA 5 acetyl salicylic acid
BSA 5 bovine serum albumin
DMEM 5 Dulbecco’s modified essential medium
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I/M 5 intima-to-media
PDGF 5 platelet-derived growth factor
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SMC 5 smooth muscle cell
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lial denudation, 2 5 internal elastic lamina (IEL) laceration,
3 5 IEL and media laceration and 4 5 external elastic
lamina laceration. All coronary segments analyzed had an
injury score greater than or equal to 3. The sections with
maximal luminal area occupied by either thrombus (3-day
time point) or intimal hyperplasia (28-day time point) were
further evaluated by computerized morphometry (Software:
NIH Image 1.60). Measurements of luminal area, thrombus
area, intimal area, medial area, intima-to-media (I/M) ratio,
vessel area and percentage of missing IEL were performed
to assess differences in degree of injury between the different
treatment groups.
Hematology and drug levels. Blood samples were ob-
tained at baseline, 10 min after the heparin bolus, 15 min
after TFPI or vehicle boluses, immediately after angioplasty
and every 24 h until euthanasia. Hematologic values in-
cluded complete blood count, activated partial thromboplas-
tin time (aPTT), thrombin time, prothrombin time and
plasma fibrinogen level (Diagnostica Stago, American Bio-
products, Parsipanny, New Jersey). Tissue factor pathway
inhibitor plasma levels were measured in a sandwich immu-
Figure 1. The histology of porcine coronary arteries 72 h after angioplasty. (A and B) coronary sections of vehicle-treated animals showing the presence
of mural thrombus (red arrows). (C and D) sections of recombinant tissue factor pathway inhibitor plus heparin-treated animals. Note the hemorrhagic
area surrounding the coronary wall (yellow arrows). (E and F) sections of recombinant tissue factor pathway inhibitor alone-treated animals, with no mural
thrombosis and no periarterial hemorrhage. Note the comparable degrees of injury, with disruption of the internal elastic lamina in all sections. (All sections
photographed at 403).










ASA 1 heparin 4.1 6 0.8 37 6 9 0.8 6 0.4 1.3 6 0.03
TFPI 1 ASA
1 heparin
4.0 6 0.7 29 6 5 0.0 6 0.0* 1.3 6 0.03
TFPI 1 ASA 3.7 6 0.5 26 6 6 0.03 6 0.02* 1.2 6 0.04
* p , 0.05 versus ASA 1 heparin.
ASA 5 acetyl salycilic acid; B/V 5 balloon/vessel; IEL 5 internal elastic lamina;
TFPI 5 tissue factor pathway inhibitor.
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noassay. The assay uses a monoclonal antibody directed
against the first Kunitz domain of human rTFPI for capture
and a fluorescein-labeled polyclonal antibody to rTFPI for
detection. All samples were assayed in triplicate. The lower
limit of quantitation was 40 ng/mL.
Cell culture studies. Human SMC were obtained from
the ascending aorta of cardiac transplant donors and grown
using an explant technique: the adventitia was removed
carefully and the media was cut into 1-cm2 segments and
incubated in culture dishes with collagenase and Dulbecco’s
modified essential medium (DMEM) containing 20% fetal
bovine serum (FBS), 100 U/mL of penicillin and
100 mg/mL of streptomycin. Cells were incubated at 37°C
with 5% CO2. Smooth muscle cell lineage was confirmed by
positive a-actin staining (M851, Dako, Carpinteria, Cali-
fornia) in more than 90% of the cells. All experiments were
performed using passages 3 to 5 of cells grown in 10% FBS.
To analyze growth cells were plated in 12-well dishes at a
density of 5 3 103 cells/well, in the presence or absence of
rTFPI (250 nM). Fresh rTFPI was added with each
medium change every 48 h. DNA synthesis was determined
by 3H-thymidine incorporation. Cells were plated in 12-
well plates (5 3 103 cells/well) and incubated for 24 h in
DMEM supplemented with 1% FBS. Smooth muscle cells
were then washed in phosphate buffered saline and incu-
bated for 24 h with 1 mCi of 3H-thymidine in DMEM plus
10% FBS in the presence or absence of rTFPI. Cells were
precipitated with 10% trichloroacetic acid for 60 min at 4°C,
solubilized with 0.1N NaOH and radioactivity measured in
a liquid scintillation counter. Experiments were done in
triplicate, using quadruplicate wells.
Vascular SMC migration assay. A modified Boyden
chamber with a polycarbonate filter with 8-mm pores
(Nucleopore, Cabin John, Maryland) was used to measure
SMC migration. The filter was coated with collagen,
0.1 mg/mL (Vitrogen 100, Centrix, California) in 0.2 M
acetic acid, 24 h before the experiment. To induce chemo-
taxis, PDGF-BB (20 ng/mL) in DMEM plus 0.2% bovine
serum albumin (BSA) was placed in the lower chamber;
0.2% BSA without PDGF was used as negative control.
Fifty mL of SMC (2 3 105 cells/mL) in DMEM, contain-
ing different concentrations of TFPI, were loaded in the
wells of the upper chamber (four wells per condition). After
a 6-h incubation at 37°C in 5% CO2, cells were gently
scraped from the upper surface of the filter, and cells on the
lower surface of the membrane were fixed with methanol
and stained with Diff Quik (Baxter, Largo, Florida). The
number of migrating cells was determined by counting four
high-power fields (3 200) in the central area of each well.
Results are expressed as mean percentage of migrating cells
after subtracting the negative control (BSA), averaging data
from six separate experiments.
Statistical analysis. Numerical data are expressed as
mean 6 standard error of the mean. Comparisons of data
among the different groups were performed using one-way
analysis of variance and Bonferroni’s test for multiple
comparisons among treatment groups, as well as unpaired
Student t test as appropriate. A p value ,0.05 was consid-
ered significant.
RESULTS
Effect of TF inhibition on acute thrombus formation.
Data from coronary specimens harvested 72 h after angio-
plasty are summarized in Table 1. The control group had a
mean mural thrombus area of 0.8 6 0.4 mm2 (Fig. 1, A and
B). In the group treated with rTFPI plus ASA plus bolus of
heparin, the thrombus area was zero (p , 0.05 versus
control), but the specimens displayed severe bruising and
hemorrhage of surrounding tissues (Fig. 1, C and D). In this
group hematomas in the surgically intervened areas, such as
the groin, were observed frequently (not shown). In the
group treated with rTFPI plus ASA (without heparin), the
thrombus area was 0.03 6 0.02 mm2 (p , 0.05 versus
control; Fig. 1, E and F); no bleeding complications were
noted.
Effect of TF inhibition on intimal hyperplasia. Speci-
mens harvested 28 days after angioplasty were analyzed for
intimal hyperplasia. Coronary artery sections in the control
group (n 5 12) had a mean intimal area of 3.3 6 0.4 mm2,
Figure 2. The morphometry of coronary arteries from control and rTFPI-treated swine. (A) Standardized intimal area or intima-to-media ratio of control
and rTFPI-treated animals. (B) percentage luminal narrowing in both treatment groups, control and rTFPI. I/M 5 intima-to-media; rTFPI 5
recombinant tissue factor pathway inhibitor.
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mean I/M ratio of 3.9 6 0.7 mm2 and luminal narrowing of
61 6 3% (Fig. 2 and 3, A to C). The rTFPI-treated group
(n 5 12) had a mean intimal area of 1.2 6 0.4 mm2, mean
I/M ratio of 1.5 6 0.5 and luminal narrowing of 34 6 5%
(p , 0.05 vs. control; Fig. 2 and 3, D to F).
rTFPI plasma levels and hematology. The plasma levels
of rTFPI after bolus and infusion are shown in Figure 4.
Recombinant TFPI alone induced a modest prolongation of
the aPTT (Fig. 5), as well as a two-fold increase in
thrombin time. No changes in prothrombin time or fibrin-
ogen levels were observed in any of the different treatment
groups. Administration of TFPI plus heparin increased the
aPTT markedly. No bleeding complications were noted in
animals receiving rTFPI plus ASA or in the control group.
The rTFPI plus heparin bolus regimen caused a high
incidence of hematomas in the groin and other areas of
surgical manipulation, in addition to severe bruising and
gross hemorrhage in the pericoronary tissues of all animals
(not shown).
rTFPI inhibits SMC migration. Recombinant TFPI, at a
concentration of 250 nM, did not inhibit serum-induced
3H-thymidine incorporation (8,388 6 1,433 cpm vs.
6,508 6 172 cpm in cells grown in 10% FBS; p 5 NS) or
cell number in cultured SMC (Fig. 6). In contrast, rTFPI
Figure 3. The proliferative response in porcine coronary arteries 28 days after angioplasty. Representative coronary sections of control (A to C) and
recombinant tissue factor pathway inhibitor-treated (D to F) animals. Note the internal elastic lamina disruption in all sections and larger amounts of
intimal hyperplasia in the sections from controls compared with tissue factor pathway inhibitor-treated group. (All sections photographed at 403.)
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inhibited PDGF-inducible SMC migration in a dose-
dependent fashion (Fig. 7).
DISCUSSION
This study reports on the effects of rTFPI in a porcine
model of coronary angioplasty. The results further support
the concept that inhibition of thrombin and acute thrombus
formation can reduce the development of intimal hyperpla-
sia and provide new evidence for a synergistic anticoagulant
effect of rTFPI and unfractionated heparin.
Tissue factor is thought to be critical in initiating throm-
botic events after plaque rupture—either spontaneous or
induced mechanically and, thereby, is likely to have a
significant role in promoting intimal hyperplasia leading to
restenosis after injury (19,27–32). Therefore, specific inhi-
bition of TF is a potential therapeutic approach to prevent
clinical events subsequent to coronary interventions. The
antithrombotic efficacy of rTFPI has been shown in models
of venous thrombosis in rabbits (21) and arterial thrombosis
in dogs, where it inhibited reocclusion after thrombolysis
with tPA (22,33). In this study inhibition of TF activity by
rTFPI abolished acute thrombus formation after coronary
angioplasty in a porcine model.
Synergistic effect of rTPI and heparin. The association of
rTFPI with heparin had a synergistic anticoagulant effect
and resulted in a high incidence of bleeding in the injured
areas. The plasma levels of TFPI measured in the acute
phase after angioplasty in this study were within the
therapeutic range used in previous studies (9,19). Heparin is
known to induce the release of TFPI from endothelial cells
in a concentration- and time-dependent fashion (34–36).
However, it is unlikely that this is the only responsible
mechanism for the observed synergistic effect because the
levels of heparin-releasable TFPI reported in previous
studies are rather insignificant (50 to 100 ng/mL) (36) when
compared with the levels of TFPI obtained in our study (2.7
to 3.2 mg/mL). Recombinant TFPI administered in com-
bination with aspirin only induced a two-fold increase in
aPTT ratio without periprocedural thrombotic complica-
tions. These observations are of relevance because rTFPI is
a powerful antithrombotic with potential clinical application
in the near future. Routine use of heparin during percuta-
neous coronary interventions appears unnecessary when
Figure 5. Activated partial thromboplastin time monitoring during TFPI
treatment. Activated partial thromboplastin time values at baseline and
different times over a 72-h period after angioplasty for the three treatment
groups (UFH plus ASA, heparin bolus plus aspirin; UFH plus ASA plus
TFPI, heparin bolus plus ASA plus TFPI; ASA plus TFPI, ASA plus
rTFPI). Note the synergistic anticoagulant effect of TFPI and heparin
compared with the modest increase in aPTT elicited by TFPI alone.
Long-dash line 5 UFH1ASA; solid line 5 UFH1ASA1TFPI; short-
dash line 5 ASA1TFPI. aPTT 5 activated partial thromboplastin time;
ASA 5 acetyl salicylic acid; PTCA 5 percutaneous transluminal coronary
angioplasty; TFPI 5 tissue factor pathway inhibitor; UFH 5 unfraction-
ated heparin.
Figure 4. Plasma levels of TFPI. Plasma levels of TFPI at different times
before and after angioplasty during continuous intravenous administration
of recombinant TFPI. PTCA 5 percutaneous transluminal coronary
angioplasty; TFPI 5 tissue factor pathway inhibitor.
Figure 6. The effect of tissue factor pathway inhibitor on smooth muscle
cell proliferation. Seven-day growth curve of human aortic smooth muscle
cells in the presence or absence of rTFPI. Short-dash line 5 1% FBS; solid
line 5 10% FBS; long-dash line 5 10% FBS 1 rTFPI. FBS 5 fetal bovine
serum; rTFPI 5 recombinant tissue factor pathway inhibitor.
Figure 7. The effect of TFPI on smooth muscle cell migration.
Concentration-dependent inhibition of human aortic smooth muscle cell
migration by recombinant TFPI. All concentrations expressed as nM.
BSA 5 bovine serum albumin; HPF 5 high power field; TFPI 5 tissue
factor pathway inhibitor.
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rTFPI is used or should be kept at a minimum dose to
ensure adequate anticoagulation without bleeding compli-
cations.
TF inhibition reduces intimal hyperplasia. In this study
TF inhibition with rTFPI administered for 14 days after
coronary angioplasty reduced intimal hyperplasia. The for-
mation of a platelet-rich thrombus at the site of vascular
injury may serve as a matrix for SMC migration and
proliferation because thrombin is a growth factor for SMC
(14). In this context TF inhibition and, subsequently,
thrombin generation by rTFPI has been shown previously
to reduce the development of intimal hyperplasia after
angioplasty in other experimental models such as the pig
carotid artery (9) and rabbit femoral artery (10). A factor Xa
inhibitor (recombinant tick anticoagulant peptide) also has
been shown to inhibit intimal hyperplasia in the pig
coronary (11).
rTFPI inhibits SMC migration. To further define the
mechanism of action of rTFPI, we also studied the effects of
rTFPI on SMC migration and proliferation. This study
demonstrates that rTFPI inhibits PDGF-BB-induced hu-
man SMC migration in a dose-dependent fashion, whereas
it does not interfere with serum-induced SMC growth. The
beneficial effect of rTFPI has been attributed largely to the
inhibition of acute thrombus formation after injury. Our
findings indicate that, in addition to its antithrombotic
properties and the extended benefit of acute thrombus
inhibition on intimal hyperplasia, rTFPI may reduce neo-
intimal thickening, in part, by direct effects on SMC
migration. It should be noted that no effect on SMC
proliferation was seen in culture.
The effect of TFPI on PDGF-mediated SMC migration
is intriguing. Tissue factor pathway inhibitor has not been
shown to interact directly with PDGF or its receptors, nor
is it known to bind to cell-surface molecules other than TF.
It is thus likely that the inhibition of SMC migration is due
to the interaction between TFPI and TF. One possibility is
that the binding of TFPI transduces an intracellular signal,
which inhibits migration. Although several studies have
suggested that TF may be involved in cytoplasmic signaling
(37), this remains controversial. Alternatively, SMC migra-
tion may be regulated, in part, by a product of TF catalytic
activity such as thrombin or Xa and, therefore, may be
altered by inhibiting TF activity. Sato et al. (38) found that
the TF VIIa complex stimulates SMC migration. The
mechanisms for this finding remain to be determined. We
have reported previously that the expression of active TF on
the SMC surface is transient and peaks 4 to 6 h after PDGF
stimulation (39). Under the conditions of this study, SMC
were exposed to PDGF as a chemoattractant for 6 h, well
within the time frame for the surface expression of newly
synthesized TF. It is thus possible that the migratory effect
of PDGF on SMC is mediated through the synthesis of TF.
It should be noted that Sato and colleagues (40) did not find
that TFPI inhibited SMC migration, perhaps due to dif-
ferences in the SMC (their study used rabbit SMC, whereas
ours were human) or the conditions under which they were
cultured.
Conclusions. In summary using a porcine model of coro-
nary angioplasty, we demonstrated that specific inhibition of
the TF pathway, interfering with in vivo generation of
thrombin, prevents not only acute thrombus formation but
also neointimal formation. In addition to its antithrombotic
effect, TFPI also may exert its inhibitory effect on intimal
hyperplasia by impairing SMC migration. This novel ther-
apeutic approach may be beneficial in avoiding the compli-
cations associated with percutaneous coronary interventions
although special care should be taken regarding the syner-
gistic anticoagulant potential of TFPI and heparin.
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